The aggregated results of our study, based on 7 case-control studies (23,28,29) on MTR rs1805087 polymorphism, revealed no significant differences between MTR rs1805087 polymorphism and meningioma in all the genetic models and subgroup analyses after including the large-sample size study (23). This evidence concerns the gene MTR and meningioma.